About Us

Learn more about the Society

Officers

The Society for Functional Precision Medicine arose out of recognition of the unmet need in matching cancer patients to the therapies best for them. We think there is tremendous utility in exposing patient tumor cells directly to the drugs that could be used to treat them in order to do this matching. We propose to bring cutting edge tools of tissue culture and analysis to bear on this strategy to create practical solutions. Our overriding mission is to accelerate the day when functional assays are a routine tool in the care of cancer patients. The SFPM welcomes the input and participation of any who are interested, including scientists and clinicians, patient advocates and regulators, academia as well as pharma and biotech.

Learn more about the SFPM in this recent podcast.

Anthony Letai, MD, PhD
President

Dana-Farber Cancer Institute, Harvard Medical School

Karin Langenberg, MD, PhD
Vice President

Princess Máxima Center for pediatric oncology

Keith Ligon, MD, PhD
Secretary

Dana-Farber Cancer Institute, Harvard Medical School

Jeff Tyner, PhD
Treasurer

Oregon Health Sciences University

Diana Azzam, PhD
Board Member

Florida International University

Joan Montero, PhD
Board Member

University of Barcelona

Christian Regenbrecht, PhD
Board Member - Commercial Sector

ASC Oncology

Alice Soragni, PhD
Board Member

University of California, Los Angeles

Bruce Yeager
Board Member - Commercial Sector

G2E Enterprises, Inc.